ANEB
Anebulo Pharmaceuticals Inc
NASDAQ: ANEB · HEALTHCARE · BIOTECHNOLOGY
$0.43
-11.78% today
Updated 2026-04-29
Market cap
$22.43M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.18
Dividend yield
—
52W range
$0 – $3
Volume
0.0M
Anebulo Pharmaceuticals Inc (ANEB) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| R&D | $150000.00 | $2.27M | $2.96M | $5.60M | $3.55M | $4.30M |
| SG&A | $140106.00 | $1.34M | $3.87M | $6.18M | $4.75M | $4.92M |
| Operating income | $-173351.00 | $-3.61M | $-6.83M | $-11.78M | $-8.31M | $-9.22M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-173351.00 | $-30.24M | $-6.83M | $-11.78M | $-7.79M | $-8.10M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-1.21M | $-33.85M | $-6.83M | $-11.78M | $-8.05M | — |
| Interest expense | $1286.00 | $11767.00 | $7332.00 | $0.00 | $151230.00 | $382014.00 |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-174637.00 | $-30.25M | $-6.83M | $-11.73M | $-8.20M | $-8.48M |
| Net income growth (YoY) | — | -17223.4% | +77.4% | -71.9% | +30.1% | -3.4% |
| Profit margin | — | — | — | — | — | — |